526 related articles for article (PubMed ID: 15377473)
1. The RANK/RANK ligand system is involved in interleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment.
Giuliani N; Colla S; Morandi F; Rizzoli V
Haematologica; 2004 Sep; 89(9):1118-23. PubMed ID: 15377473
[TBL] [Abstract][Full Text] [Related]
2. Lack of receptor activator of nuclear factor-kB ligand (RANKL) expression and functional production by human multiple myeloma cells.
Giuliani N; Colla S; Morandi F; Barille-Nion S; Rizzoli V
Haematologica; 2005 Feb; 90(2):275-8. PubMed ID: 15710592
[TBL] [Abstract][Full Text] [Related]
3. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation.
Nguyen AN; Stebbins EG; Henson M; O'Young G; Choi SJ; Quon D; Damm D; Reddy M; Ma JY; Haghnazari E; Kapoun AM; Medicherla S; Protter A; Schreiner GF; Kurihara N; Anderson J; Roodman GD; Navas TA; Higgins LS
Exp Cell Res; 2006 Jun; 312(10):1909-23. PubMed ID: 16600214
[TBL] [Abstract][Full Text] [Related]
4. Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation.
Sun SG; Lau YS; Itonaga I; Sabokbar A; Athanasou NA
J Pathol; 2006 May; 209(1):114-20. PubMed ID: 16482498
[TBL] [Abstract][Full Text] [Related]
5. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
[TBL] [Abstract][Full Text] [Related]
6. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
[TBL] [Abstract][Full Text] [Related]
7. New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL).
Giuliani N; Colla S; Rizzoli V
Exp Hematol; 2004 Aug; 32(8):685-91. PubMed ID: 15308315
[TBL] [Abstract][Full Text] [Related]
8. Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells.
Secchiero P; Corallini F; Barbarotto E; Melloni E; di Iasio MG; Tiribelli M; Zauli G
J Cell Physiol; 2006 Apr; 207(1):158-64. PubMed ID: 16270354
[TBL] [Abstract][Full Text] [Related]
9. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.
Giuliani N; Colla S; Sala R; Moroni M; Lazzaretti M; La Monica S; Bonomini S; Hojden M; Sammarelli G; Barillè S; Bataille R; Rizzoli V
Blood; 2002 Dec; 100(13):4615-21. PubMed ID: 12393684
[TBL] [Abstract][Full Text] [Related]
10. Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck.
Tsangari H; Findlay DM; Kuliwaba JS; Atkins GJ; Fazzalari NL
Bone; 2004 Jul; 35(1):334-42. PubMed ID: 15207775
[TBL] [Abstract][Full Text] [Related]
11. Update on the pathogenesis of osteolysis in multiple myeloma patients.
Giuliani N; Colla S; Rizzoli V
Acta Biomed; 2004 Dec; 75(3):143-52. PubMed ID: 15796087
[TBL] [Abstract][Full Text] [Related]
12. TNFalpha and PTH utilize distinct mechanisms to induce IL-6 and RANKL expression with markedly different kinetics.
Dai JC; He P; Chen X; Greenfield EM
Bone; 2006 Apr; 38(4):509-20. PubMed ID: 16316790
[TBL] [Abstract][Full Text] [Related]
13. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma.
Heider U; Langelotz C; Jakob C; Zavrski I; Fleissner C; Eucker J; Possinger K; Hofbauer LC; Sezer O
Clin Cancer Res; 2003 Apr; 9(4):1436-40. PubMed ID: 12684416
[TBL] [Abstract][Full Text] [Related]
14. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
[TBL] [Abstract][Full Text] [Related]
15. IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice.
O'Brien CA; Jilka RL; Fu Q; Stewart S; Weinstein RS; Manolagas SC
Am J Physiol Endocrinol Metab; 2005 Nov; 289(5):E784-93. PubMed ID: 15956054
[TBL] [Abstract][Full Text] [Related]
16. RANK ligand is a prerequisite for cancer-associated osteolytic lesions.
Kitazawa S; Kitazawa R
J Pathol; 2002 Oct; 198(2):228-36. PubMed ID: 12237883
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.
Kamel Mohamed SG; Sugiyama E; Shinoda K; Hounoki H; Taki H; Maruyama M; Miyahara T; Kobayashi M
Biochem Biophys Res Commun; 2005 Apr; 329(3):839-45. PubMed ID: 15752732
[TBL] [Abstract][Full Text] [Related]
18. Cytological properties of stromal cells derived from giant cell tumor of bone (GCTSC) which can induce osteoclast formation of human blood monocytes without cell to cell contact.
Nishimura M; Yuasa K; Mori K; Miyamoto N; Ito M; Tsurudome M; Nishio M; Kawano M; Komada H; Uchida A; Ito Y
J Orthop Res; 2005 Sep; 23(5):979-87. PubMed ID: 16024207
[TBL] [Abstract][Full Text] [Related]
19. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
20. Gene expression relevant to osteoclastogenesis in the synovium and bone marrow of mature rats with collagen-induced arthritis.
Kishimoto Y; Fukumoto S; Nishihara S; Mizumura H; Hirai K; Teshima R
Rheumatology (Oxford); 2004 Dec; 43(12):1496-503. PubMed ID: 15353610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]